Non-small cell lung cancer NSCLC Niet-kleincellig longkanker
Conditions
Interventions
The procedure consists of a low dose CT scan, intravenous administration of [15O]H2O and 15-minutes [15O]H2O PET scan, followed by another low dose CT scan, intravenous administration of [11C]erlotini
Sponsors
VU University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: Patients with NSCLC, planned to receive erlotinib for therapy will be included in this study. Ten evaluable patients are needed. It is expected that this number of patients will be recruited within 1 year. 1. Patients age: Between 18 and 70 years; 2. Life expectancy of at least 12 weeks; 3. Malignant lesion of at least 1.5 cm diameter within the chest as measured by CT; 4. Performance status Karnofsky index >60%; 5. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Claustrophobia; 2. Pregnant or lactating patients; 3. Metal implants in the thorax (e.g. pacemakers), interfering with PET/CT imaging; 4. Concurrent treatment with experimental drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare tumor [11C]erlotinib pharmacokinetics in NSCLC patients with and without erlotinib therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Also, to assess the relationship of venous sampling versus arterial, of tumor [11C]erlotinib uptake and blood flow with and without therapy, and to explore the usefulness of static whole body images. Also, to validate image derived input function (IDIF) against continuous arterial sampling. | — |
Outcome results
None listed